-
Mashup Score: 4
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.“Combination therapy with teclistamab plus talquetamab showed encouraging antitumor activity in a majority of patients with relapsed or refractory multiple myeloma,” Yael C. Cohen, MD, head of the myeloma
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Race, sex disparities persist in weight-loss surgery - 4 hour(s) ago
Men were less likely than women to have weight-loss surgery, and that gap has widened over time, while Black patients were less likely than those of other races to have a procedure, and that gap has narrowed slightly, new data show. “Metabolic/bariatric surgery is a safe and very effective treatment of obesity,” Alexander Turchin, MD, MS, director of quality in diabetes at Brigham and
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📰Researchers found several disparities with bariatric surgery, including that men are less likely to undergo surgery than women; and Black adults are less likely to have surgery than other racial-ethnic groups. @BrighamWomens @harvardmed @MarsApovian https://t.co/EMhJPKrWSX
-
-
Mashup Score: 0Vanzacaftor, tezacaftor, deutivacaftor similar to current cystic fibrosis standard of care - 6 hour(s) ago
Among individuals aged at least 12 years with cystic fibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor was similar or better than Trikafta depending on the endpoint, according to results published in The Lancet Respiratory Medicine.“These results demonstrate the potential for vanzacaftor-tezacaftor-deutivacaftor to further improve the lives of people with cystic fibrosis by limiting
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet-
Published in @LancetRespirMed📣: Among individuals aged at least 12 years with #CysticFibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor (#Alyftrek, @VertexPharma) was similar or better than #Trikafta depending on the endpoint. Read more⬇️ https://t.co/ZCB4buHoto
-
-
Mashup Score: 0
Frailty among patients with systemic sclerosis significantly increases the risk for mortality by nearly 10-fold, but shows the potential to improve over time, according to data published in Clinical Rheumatology. “There has been a growing burden of evidence recently in the wider literature about the importance of frailty as a determinant of outcome in chronic disease,” Jessica L.
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
😟 #SystemicSclerosis patients who qualified as "frail" had 📈10x the mortality risk in a study from Dr. Jessica Fairley @StVincentsMelb and colleagues 💡 However, there may be "an important window to intervene with simple strategies"... Learn more ⬇️ https://t.co/6XiCcajERk
-
-
Mashup Score: 0
Stand-alone canaloplasty and trabeculotomy with the Omni surgical system showed positive real-world outcomes in reducing IOP and medication use, according to a study published in American Journal of Ophthalmology. “This study is both significant and unique, given its real-world design and considerably larger scale compared to previous studies on stand-alone canaloplasty and trabeculotomy
Source: www.healio.comCategories: General Medicine News, OphthalmologyTweet-
Stand-alone #canaloplasty and #trabeculotomy with the Omni surgical system showed: 👉 #IOP reductions. 👉Reductions in medication use. #OcularSurgeryNews #glaucoma @SightSciences https://t.co/akBpw0V0kK https://t.co/AMWLHeWvNc
-
-
Mashup Score: 4Linsitinib for thyroid eye disease shows proptosis reduction, safety in phase 2b/3 trial - 11 hour(s) ago
Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.
Source: www.healio.comCategories: General Medicine News, OphthalmologyTweet-
Linsitinib, an oral small molecule, demonstrated #proptosis reduction and safety in patients with #thyroideyedisease. @RayDouglasMDPHD, chief scientific officer at @SlingTX, provides insight🔗 #OcularSurgeryNews #Ophthalmology https://t.co/kJFvgcgaD7 https://t.co/3X8DxA0fYJ
-
-
Mashup Score: 0Race, sex disparities persist in weight-loss surgery - 12 hour(s) ago
Men were less likely than women to have weight-loss surgery, and that gap has widened over time, while Black patients were less likely than those of other races to have a procedure, and that gap has narrowed slightly, new data show. “Metabolic/bariatric surgery is a safe and very effective treatment of obesity,” Alexander Turchin, MD, MS, director of quality in diabetes at Brigham and
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📰Researchers found several disparities with bariatric surgery, including that men are less likely to undergo surgery than women; and Black adults are less likely to have surgery than other racial-ethnic groups. @BrighamWomens @harvardmed @MarsApovian https://t.co/EMhJPKrWSX
-
-
Mashup Score: 5
Billing patients for their messages in a patient portal led to a moderate reduction in questions for one large integrated health care provider but was generally accepted by clinicians, according to the results of recent researchA survey of clinicians who participated in the program found that a slim majority said they were “satisfied” or “very satisfied” with the billing
Source: www.healio.comCategories: General Medicine News, General HCPsTweet-
🩺 New research in @AnnalsofIM evaluated billing portal messages, an increasingly popular method of patient-provider communication since the pandemic. Two @AOAforDOs physicians offered their perspectives on the results. Read more 🔗⬇️ https://t.co/j22W61HQu0
-
-
Mashup Score: 3FDA bans red dye popular in candy, other ultraprocessed foods - 12 hour(s) ago
The FDA announced a ban on the controversial red dye no. 3, which gives food and drinks a bright, cherry red color and has also been associated with cancer in laboratory rats.In a constituent update, the agency said it is revoking the dye’s authorization based on the Delaney Clause of the Federal Food, Drug and Cosmetic Act, which states the FDA cannot authorize a color or food additive
Source: www.healio.comCategories: General Medicine News, General HCPsTweet-
🩺 The #FDA announced a ban on the controversial #reddye no. 3, which gives food and drinks a bright, cherry red color and has also been associated with cancer in laboratory rats. #HealthNews Read more 🔗⬇️ https://t.co/xmFM5MED88
-
-
Mashup Score: 6IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s - 12 hour(s) ago
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease, Lilly reported. Previously approved for ulcerative colitis in October 2023, Omvoh (mirikizumab-mrkz) enters an increasingly crowded IBD drug market following the approval of rival
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
🚨BREAKING NEWS🚨 @US_FDA has approved @EliLillyandCo's #Omvoh 💊 for the treatment of moderately to severely active #Crohns disease, making it the 2️⃣nd interleukin-23p19 specific inhibitor approved for both major types of #IBD. Learn more 🔽🔽 https://t.co/GaS461rOlD
-
The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma. Nearly two-thirds of patients in the study developed grade 3 or grade 4 infections. #Talvey #Tecvayli https://t.co/qfQWg5Sy5B